



The ACME Laboratories Ltd.
MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001:2008

CERTIFIED COMPANY

www.acmeglobal.com

Ref. No. ACME /CA/CS/0666/2016

13 November 2016

The Chairman

Bangladesh Securities and Exchange Commission
Jibon Bima Tower (15th, 16th & 20th Floor)
10, Dilkusha Commercial Area
Dhaka-1000


Kind Attention: Mr. Kamrul Anam Khan, Director

Subject: Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd.

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 66th Meeting held on 13 November 2016 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.


(Mizanur Rahman Sinha)
Managing Director

Enclosure: As stated above

Copy to: 01. The Managing Director, Dhaka Stock Exchange Limited
02. The Managing Director, Chittagong Stock Exchange Limited
03. The Chief Executive Officer, ICB Capital Management Limited




Corporate Office:

Court de la ACME
1/4, Kallayanpur, Mirpur Road
Dhaka-1207, Bangladesh.

Plant:

Dhamrai, Dhaka, Bangladesh.
Phone : 88-02-9352901-02
06222-88035, 88042, 88047
Fax : 88-02-9340146



Auditors' Report




Name of Client

The ACME Laboratories Ltd.
Utilization of IPO Proceeds
for the month ended 31 October 2016

পিনাকী এণ্ড কোম্পানী
Pinaki & Company

AHSANDELL, 2/A, Myrmensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh
Tel # 966-0944, 966-5095, Fax # 88-02-9672726
E-mail : pinaki_co@yahoo.com



AUDITORS' REPORT
on
Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of **The ACME Laboratories Ltd.** for the month ended 31 October 2016.

Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing (BSA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated 15 March 2016 gives a true and fair view of the statement for the month ended 31 October 2016 and comply with the prospectus.

As per TOR, We draw attention to the following matter:

1. The Company has utilized cumulative amounting to Tk.88,795,524 up to 31 October 2016 out of which amounting Tk. 18,924,748 is utilized during the month of October 2016 in respect of Civil Construction of Steroid and Hormone project.
2. The Company has also utilized cumulative amounting to Tk. 68,291,870 up to 31 October 2016 as IPO expenses and during the month of October 2016, no IPO expenses incurred from IPO proceeds fund.

We also state that:

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) Utilization of IPO proceeds is being under completion within the time frame as specified in the prospectus;
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus;
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date : 14.11.2016.....
Dhaka.

Pinaki & Co
Pinaki & Company
Chartered Accountants



পিনাকী এণ্ড কোম্পানী

Pinaki & Company

Chartered Accountants



The ACME Laboratories Ltd. Statement of Utilization of IPO Proceeds For the month ended 31 October 2016

For the month ended 31 October 2010											
Sl No.	Projects	Estimated cost for Project Implementation as per Prospectus		Estimated Time for completion as per Prospectus	Investment/Expenses so far made (up to 31 October 2016)			Investment/Expenses Yet to be made		Remarks	
		Cost Breakdown	Amount		Upto previous Month	During the Month	Upto this Month	Amount	%		
1	Steroid and Hormone	Civil Construction	335,800,000	Within 2 years of receiving IPO fund	66,745,776	18,924,748	85,670,524	250,129,476	74.49%		
		Machinery & Equipment	598,600,000		-	-	-	598,600,000	100%		
		Utility	339,600,000		-	-	-	339,600,000	100%		
		Wharehouse	39,500,000		-	-	-	39,500,000	100%		
		Vehicle	5,000,000		3,125,000	3,125,000	1,875,000	37.5%			
		Consultancy fee	26,300,000		-	-	-	26,300,000	100%		
		Contingencies	13,200,000								
		Sub Total	1,358,000,000		69,870,776	18,924,748	88,795,524	1,269,204,476	93.46%		
2	Oncology	Civil Construction	335,800,000	Within 2.5 years of receiving IPO fund	-	-	-	335,800,000	100%		
		Machinery & Equipment	367,000,000		-	-	-	367,000,000	100%		
		Utility	350,000,000		-	-	-	350,000,000	100%		
		Wharehouse	50,000,000		-	-	-	50,000,000	100%		
		Vehicle	5,000,000		-	-	-	5,000,000	100%		
		Consultancy fee	22,100,000		-	-	-	22,100,000	100%		
		Contingencies	11,100,000								
		Sub Total	1,141,000,000					1,141,000,000	100%		
3	Ayurvedic, Modern Herbal and Neutraceuticals	Civil Construction	417,500,000	Within 2.5 years of receiving IPO fund	-	-	-	417,500,000	100%		
		Machinery & Equipment	857,200,000		-	-	-	857,200,000	100%		
		Utility	404,000,000		-	-	-	404,000,000	100%		
		Wharehouse	11,000,000		-	-	-	11,000,000	100%		
		Vehicle	5,000,000		-	-	-	5,000,000	100%		
		Consultancy fee	33,900,000		-	-	-	33,900,000	100%		
		Contingencies	16,900,000					16,900,000	100%		
		Sub Total	1,745,500,000					1,745,500,000	100%		
4	IPO Expenses		68,291,870	N/A	68,291,870	-	68,291,870	100.00%	0%		
Grand Total			4,312,791,870		138,162,646	18,924,748	157,087,394	4,155,704,476	96.36%		

On Behalf of Board

(Folzia Haque, FCA)
Independent Director & Chairman of the Audit Committee

(Mizanur Rahman Sinha)
Managing Director

(Afzalur Rahman Sinha)
Chairman

Pinaki & Co 14.11.16
Pinaki & Company
Chartered Accountants

The ACME Laboratories Ltd.

Reconciliation Statement of IPO Proceeds
For the Month Ended 31 October 2016

Cash at Bank as at 31 October 2016

Standard Chartered Bank Bangladesh, ESCREW A/C No: 02-1111195-03	Workings-1	14,236,948.68
Standard Chartered Bank Bangladesh, SND A/C No: 02-1111195-01	Workings-2	440,031,893.77

Workings-1

Standard Chartered Bank Bangladesh, ESCREW A/C No: 02-1111195-03

Particulars	Amount in BDT
Opening Balance as per Bank Statement as at 01 October 2016	14,236,948.68
Add : Received	-
Less: Payment	-
Closing Balance as per Bank Statement as at 31 October 2016	14,236,948.68

Workings-2

Standard Chartered Bank Bangladesh, SND A/C No: 02-1111195-01

Particulars	Amount in BDT
Opening Balance as per Bank Statement as at 01 October 2016	457,406,731.77
Add : Received	1,549,910.00
-Excess amount of IPO expenses with compared to the declared amount which was supposed to be paid from equity but inadvertently paid from SND accounts. During the month, re-transferred the same to SND account	1,549,910.00
Less: Payment for the Purpose of	18,924,748.00
- Civil Construction of Steroid and Hormone Project	18,924,748.00
Closing Balance as per Bank Statement as at 31 October 2016	440,031,893.77


(Fouzia Haque, FCA)

Independent Director &
Chairman of the Audit Committee


(Mizanur Rahman Sinha)
Managing Director


(Afzalur Rahman Sinha)
Chairman


Pinaki & Company
Chartered Accountants